Atara Biotherapeutics
ATRA · NASDAQ
$9.16+$0.20 (+2.23%)TodayMarket closed ·
Prev close $8.96
EPS: actual vs estimate
Beat the estimate in 6 of the last 8 quarters, by 95.8% on average
Reported EPS
Estimated EPS
| Quarter | Estimate | Reported | Surprise |
|---|---|---|---|
| Q2 FY26 | -$0.3213 | -$0.32 | +0.4% |
| Q1 FY26 | -$0.4131 | -$0.29 | +29.8% |
| Q4 FY25 | -$0.1748 | -$0.25 | −43.0% |
| Q3 FY25 | -$0.8772 | -$0.32 | +63.5% |
| Q2 FY25 | -$0.4692 | $0.19 | +140.5% |
| Q1 FY25 | -$2.02 | $3.50 | +273.3% |
| Q4 FY24 | -$3.65 | -$1.19 | +67.4% |
| Q3 FY24 | -$1.97 | -$2.93 | −48.6% |
Earnings calls
- Goldman Sachs 45th Annual Global Healthcare Conference
- J.P. Morgan 42nd Annual Healthcare Conference 2024
- ATRA - Earnings call 3 2023
- Citi 18th Annual BioPharma Conference
- Goldman Sachs 44th Annual Global Healthcare Conference
- 41st Annual J.P. Morgan Healthcare Conference
- Earnings call Q3 2022
- Citi's 17th Annual BioPharma Conference
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.